| Khola Qamar, MD | |
|
140 Hospital Dr Ste 307, Bennington, VT 05201 | |
| (802) 447-4555 | |
| (802) 447-0996 |
| Full Name | Khola Qamar |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 140 Hospital Dr Ste 307, Bennington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083974299 | NPI | - | NPPES |
| 042.0014066 | Other | VT | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 042.0014066 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckenzie-willamette Medical Center | Springfield, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ehg Of Oregon, P.c. | 2365867397 | 7 |
News Archive
A team of Montr-al researchers at the IRCM led by Dr. Nabil G. Seidah, in collaboration with Dr. William C. Wetsel's team at Duke University in the United States, discovered that the protein PC7 plays a critical role in the brain by affecting certain types of cognitive performance such as anxiety, learning and emotional memory. Their results, recently published in the scientific journals Proceedings of the National Academy of Sciences (PNAS) and Nature, could have a significant impact on regulating behaviour related to anxiety disorders and trauma.
African Americans have higher blood levels of a protein associated with increased heart-disease risk than European Americans, despite higher "good" HDL cholesterol and lower "bad" triglyceride levels. This contradictory observation now may be explained, in part, by a genetic variant identified in the first large-scale, genome-wide association study of this protein involving 12,000 African American and Hispanic American women.
Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.
As enrollment packets for insurance benefits begin to land on workers' desks or arrive in the mail, pay attention. This is not the year to simply renew last year's choices without studying the options. The first baby steps of the nation's health care overhaul have taken effect.
For patients with cancer, "prehabilitation"— interventions given between the time of diagnosis and the start of treatment—has the potential to reduce complications from treatments and improve physical and mental health outcomes, according to a report in the August American Journal of Physical Medicine & Rehabilitation.
› Verified 8 days ago
| Entity Name | Ehg Of Oregon, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912521105 PECOS PAC ID: 2365867397 Enrollment ID: O20200806003490 |
News Archive
A team of Montr-al researchers at the IRCM led by Dr. Nabil G. Seidah, in collaboration with Dr. William C. Wetsel's team at Duke University in the United States, discovered that the protein PC7 plays a critical role in the brain by affecting certain types of cognitive performance such as anxiety, learning and emotional memory. Their results, recently published in the scientific journals Proceedings of the National Academy of Sciences (PNAS) and Nature, could have a significant impact on regulating behaviour related to anxiety disorders and trauma.
African Americans have higher blood levels of a protein associated with increased heart-disease risk than European Americans, despite higher "good" HDL cholesterol and lower "bad" triglyceride levels. This contradictory observation now may be explained, in part, by a genetic variant identified in the first large-scale, genome-wide association study of this protein involving 12,000 African American and Hispanic American women.
Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.
As enrollment packets for insurance benefits begin to land on workers' desks or arrive in the mail, pay attention. This is not the year to simply renew last year's choices without studying the options. The first baby steps of the nation's health care overhaul have taken effect.
For patients with cancer, "prehabilitation"— interventions given between the time of diagnosis and the start of treatment—has the potential to reduce complications from treatments and improve physical and mental health outcomes, according to a report in the August American Journal of Physical Medicine & Rehabilitation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Khola Qamar, MD 140 Hospital Dr Ste 307, Bennington, VT 05201-5018 Ph: (802) 447-4555 | Khola Qamar, MD 140 Hospital Dr Ste 307, Bennington, VT 05201 Ph: (802) 447-4555 |
News Archive
A team of Montr-al researchers at the IRCM led by Dr. Nabil G. Seidah, in collaboration with Dr. William C. Wetsel's team at Duke University in the United States, discovered that the protein PC7 plays a critical role in the brain by affecting certain types of cognitive performance such as anxiety, learning and emotional memory. Their results, recently published in the scientific journals Proceedings of the National Academy of Sciences (PNAS) and Nature, could have a significant impact on regulating behaviour related to anxiety disorders and trauma.
African Americans have higher blood levels of a protein associated with increased heart-disease risk than European Americans, despite higher "good" HDL cholesterol and lower "bad" triglyceride levels. This contradictory observation now may be explained, in part, by a genetic variant identified in the first large-scale, genome-wide association study of this protein involving 12,000 African American and Hispanic American women.
Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.
As enrollment packets for insurance benefits begin to land on workers' desks or arrive in the mail, pay attention. This is not the year to simply renew last year's choices without studying the options. The first baby steps of the nation's health care overhaul have taken effect.
For patients with cancer, "prehabilitation"— interventions given between the time of diagnosis and the start of treatment—has the potential to reduce complications from treatments and improve physical and mental health outcomes, according to a report in the August American Journal of Physical Medicine & Rehabilitation.
› Verified 8 days ago
Dr. Patrick J Tangney, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr Ste 307, Bennington, VT 05201 Phone: 802-447-4555 Fax: 802-440-6087 | |
Dr. David M Gorson, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 140 Hospital Dr, Suite 301, Bennington, VT 05201 Phone: 802-442-3022 Fax: 802-442-4874 | |
Mr. Eric Steven Seyferth, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr, Suite 310, Bennington, VT 05201 Phone: 802-442-7855 Fax: 802-442-6638 | |
Ms. Ashley N Maranino, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr, Suite 104, Bennington, VT 05201 Phone: 802-447-1536 | |
Scott W Rogge, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Drive, Suite 312, Bennington, VT 05201 Phone: 802-442-0800 Fax: 802-442-0212 | |
David M Sischy, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 140 Hospital Dr, Bennington, VT 05201 Phone: 802-447-8650 Fax: 802-447-8653 |